NEW YORK (GenomeWeb) – Myriad Genetics reported after the close of the market on Tuesday that its fiscal first quarter 2019 revenues rose 13 percent year over year.

For the three months ended Sept. 30, total revenues rose to $202.3 million from $178.8 million in the year-ago quarter, just shy of analysts' average estimate of $202.4 million.